Scarica l'app Stockscreener
0.40
17.65%
0.06
Dopo l'orario di chiusura:
.41
0.010
+2.50%
Precedente Chiudi:
$0.34
Aprire:
$0.3531
Volume 24 ore:
1.78M
Relative Volume:
0.94
Capitalizzazione di mercato:
$26.61M
Reddito:
-
Utile/perdita netta:
$-17.78M
Rapporto P/E:
-0.7283
EPS:
-0.5492
Flusso di cassa netto:
$-10.52M
1 W Prestazione:
+19.44%
1M Prestazione:
+62.27%
6M Prestazione:
-39.58%
1 anno Prestazione:
-75.00%
Intervallo 1D:
$0.3505
$0.4069
Intervallo di 1 settimana:
$0.31
$0.4069
Portata 52W:
$0.2201
$2.00
Fibrobiologics Inc Stock (FBLG) Company Profile
Nome
Fibrobiologics Inc
Settore
Industria
Telefono
281-671-5150
Indirizzo
455 E. MEDICAL CENTER BLVD, HOUSTON
Confronta FBLG con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FBLG
Fibrobiologics Inc
|
0.40 | 22.62M | 0 | -17.78M | -10.52M | -0.5492 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.41 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.55 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
814.74 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
357.98 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.32 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Fibrobiologics Inc Stock (FBLG) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-12 | Iniziato | Rodman & Renshaw | Buy |
| 2024-10-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-09-24 | Iniziato | Maxim Group | Buy |
Fibrobiologics Inc Borsa (FBLG) Ultime notizie
FibroBiologics to Present at the DealFlow Discovery Conference - manilatimes.net
Biotech with 270+ patents meets investors at DealFlow Discovery - Stock Titan
Risk Recap: Is FibroBiologics Inc stock a smart retirement pickJuly 2025 Chart Watch & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Aug EndMonth: Why retail investors favor FibroBiologics Inc stockJuly 2025 Snapshot & Safe Swing Trade Setups - Bộ Nội Vụ
Levels Update: Why retail investors favor FibroBiologics Inc stock2025 AllTime Highs & Long-Term Safe Investment Ideas - Bộ Nội Vụ
How FibroBiologics Inc. stock benefits from strong dollarWeekly Trade Summary & Long-Term Growth Stock Strategies - Улправда
Why analysts remain bullish on FibroBiologics Inc. stockTrade Risk Summary & Consistent Profit Trading Strategies - Улправда
Will FibroBiologics Inc. stock remain a Wall Street favoriteWeekly Loss Report & Reliable Price Action Trade Plans - Улправда
Why FibroBiologics Inc. stock is a must watch in 2025July 2025 Breakouts & Verified Swing Trading Watchlists - Улправда
FibroBiologics faces Nasdaq delisting, plans reverse split - MSN
FBLG: Phase 1/2 Trial in Diabetic Foot Ulcers to Initiate in 1Q26 - Yahoo Finance
FibroBiologics to begin diabetic foot ulcer clinical trial in Q1 2026 - Investing.com Nigeria
Why FibroBiologics Inc. (SG0) stock attracts wealthy investorsStock Market Trends & Minimize Portfolio Damage with Warnings - ulpravda.ru
FibroBiologics CEO Issues Letter to Shareholders - markets.businessinsider.com
FibroBiologics to begin diabetic foot ulcer clinical trial in Q1 2026 By Investing.com - Investing.com South Africa
How a little-known biotech uses fibroblast cells against chronic disease - Stock Titan
FibroBiologics (NASDAQ:FBLG) Given “Buy” Rating at D. Boral Capital - Defense World
How interest rate cuts could boost FibroBiologics Inc. stock2026 world cup usa national team round of 16 defensive leaders possession football expert forecast insights - Улправда
FibroBiologics (FBLG) Rating Maintained as "Buy" by D. Boral Cap - GuruFocus
FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference - The Manila Times
FibroBiologics reports positive results for disc degeneration therapy By Investing.com - Investing.com Nigeria
FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte Spheroid Therapy for Degenerative Disc Disease - marketscreener.com
FibroBiologics reports positive results for disc degeneration therapy - Investing.com
FibroBiologics Announces Positive Preclinical Results for a - GlobeNewswire
Fibrobiologics files IND for CYPS-317 to treat psoriasis - BioWorld MedTech
About Us - FinancialContent
FibroBiologics Advances Psoriasis Therapy Pipeline Through FDA IND Filing For CYPS317 - Voice Of HealthCare
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE), FibroBiologics, Inc. (FBLG) and Corcept Therapeutics (CORT) - The Globe and Mail
FibroBiologics (NASDAQ:FBLG) Given “Buy” Rating at HC Wainwright - Defense World
FibroBiologics Faces Nasdaq Delisting, Plans Reverse Split - TipRanks
FibroBiologics receives Nasdaq delisting notice, requests hearing to appeal By Investing.com - Investing.com South Africa
FibroBiologics receives Nasdaq delisting notice, requests hearing to appeal - Investing.com
FibroBiologics Received Notice of Delisting - TradingView — Track All Markets
FibroBiologics stock maintains Buy rating at H.C. Wainwright on psoriasis IND filing - Investing.com Canada
FibroBiologics stock maintains Buy rating at H.C. Wainwright on psoriasis IND filing By Investing.com - Investing.com South Africa
FBLG: HC Wainwright & Co. Reiterates Buy Rating with Price Targe - GuruFocus
Fibrobiologics stock rises after FDA filing for psoriasis treatment - Investing.com India
Fibrobiologics stock rises after FDA filing for psoriasis treatment By Investing.com - Investing.com South Africa
FibroBiologics files IND application for psoriasis treatment By Investing.com - Investing.com Nigeria
FibroBiologics files IND application for psoriasis treatment - Investing.com India
FibroBiologics Announces IND Filing for CYPS317 Therapy for Moderate to Severe Psoriasis - Quiver Quantitative
Fibrobiologics Inc Azioni (FBLG) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.92%
2.36%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):